Cancer Health Treatment Update News From the AACR Virtual Annual Meeting See all our reports from one of the most anticipated cancer research conferences -- this year held online. Cancer Patients With COVID-19 May Have Higher Risk of Severe Illness and Death Cancer type, stage and treatment appear to affect the likelihood of poor outcomes. How to Prepare For a Virtual Visit With Your Oncologist Once you become comfortable with virtual visits, you can feel just like you’re in the clinic—while in the comfort of your own home. For all of Cancer Health's coverage of the novel coronavirus and COVID-19, click here. FDA Approves Less Frequent Keytruda Dosing Schedule A study of melanoma patients found that treatment every six weeks is comparable to every three weeks. Cardiovascular Care for Cancer Survivors a Blind Spot for Some Physicians The National Comprehensive Cancer Network recently released guidelines to try to bridge this gap in care. Health Insurance Coverage Disruptions Affect Cancer Care and Survival New review finds breaks in coverage affect cancer treatment and outcomes. Cancer Health Spring 2020 Check out our new print edition! Advertisement Newsfeed Fear Of Coronavirus Propels Some Smokers To Quit UPDATED: Who Is Most Susceptible to the New Coronavirus? COVID-19 Patients With Cancer in New York City Have a High Death Rate Older Immigrants Face More Challenges During Pandemic Blog: Food and Drug Administration (FDA) FDA Approves Jelmyto for Upper Tract Urothelial Cancer FDA Approves Koselugo for Pediatric Neurofibromatosis FDA Approves Braftovi Combination for Metastatic Colon Cancer FDA Requests Removal of All Ranitidine Products (Zantac) from the Market Newsfeed Fear Of Coronavirus Propels Some Smokers To Quit UPDATED: Who Is Most Susceptible to the New Coronavirus? COVID-19 Patients With Cancer in New York City Have a High Death Rate Older Immigrants Face More Challenges During Pandemic Blog: Food and Drug Administration (FDA) FDA Approves Jelmyto for Upper Tract Urothelial Cancer FDA Approves Koselugo for Pediatric Neurofibromatosis FDA Approves Braftovi Combination for Metastatic Colon Cancer FDA Requests Removal of All Ranitidine Products (Zantac) from the Market

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@cancerhealth.com. Please remember to add update@cancerhealth.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is: